{"title":"Effects of Etifoxine and Alprazolam on Pregnenolone, Cortisol, and 18-kDa Translocator Protein in Healthy Men: A Placebo-Controlled Study.","authors":"Marco Riebel, Lisa-Marie Brunner, Doris Melchner, Anett Dörfelt, Jens Volkmar Schwarzbach, Rainer Rupprecht, Caroline Nothdurfter","doi":"10.1055/a-2935-8784","DOIUrl":"https://doi.org/10.1055/a-2935-8784","url":null,"abstract":"<p><strong>Abstract: </strong>INTRODUCTION:: The non-benzodiazepine anxiolytic etifoxine is hypothesized to act as a neurosteroidogenic agent via the 18-kDa translocator protein. In a placebo controlled design, we compared its steroidogenic effects with those of alprazolam.</p><p><strong>Abstract: </strong>METHODS:: In a double-blind within-subject design, healthy male participants (<i>N</i>=29) received etifoxine (150 mg/d), alprazolam (1.5 mg/d), and placebo in randomised order for 5 days. Pregnenolone expression and cortisol expression were assessed at the end of each treatment in the morning, and at four time points in the afternoon. Thrombocyte 18-kDa translocator protein expression was measured in the morning.</p><p><strong>Abstract: </strong>RESULTS:: Analysis of morning samples revealed higher 18-kDa translocator protein expression (<i>χ</i> <sup>2</sup>=7.41 and <i>p</i>=0.025) after etifoxine intake compared to alprazolam intake (<i>p</i>=0.025). Both alprazolam and etifoxine were associated with lower pregnenolone levels (<i>p</i><0.005). The 18-kDa translocator protein did not mediate the medication effects on pregnenolone (average causal mediation effects for etifoxine vs. placebo contrast: <i>p</i>=0.276). Afternoon measurements showed that alprazolam reduced cortisol (<i>χ</i> <sup>2</sup>=66.76, <i>p</i><0.001), and that both alprazolam and etifoxine reduced pregnenolone levels (<i>χ</i> <sup>2</sup>=31.75, <i>p</i><0.001). State anxiety was only marginally lowered by medication (<i>p</i>=0.092), and no biological markers-cortisol, pregnenolone, or 18-kDa translocator protein-predicted anxiety ratings (all <i>p</i> > 0.40).</p><p><strong>Abstract: </strong>CONCLUSIONS:: We confirmed the effects of benzodiazepines on cortisol and pregnenolone levels in healthy male participants. Etifoxine administration was associated with a decrease in peripheral plasma pregnenolone. Taken together, however, plasma pregnenolone levels do not seem to reflect etifoxine binding to 18-kDa translocator protein and central anxiolytic mechanisms in humans.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pipamperone metabolism by various recombinant cytochrome preparations.","authors":"Tamara Pfaff, Burkhard Hinz, Udo I Walther","doi":"10.1055/a-2894-5577","DOIUrl":"10.1055/a-2894-5577","url":null,"abstract":"<p><strong>Introduction: </strong>The evaluation of pharmacokinetic interactions is based on the knowledge of enzymatic metabolization by cytochrome 450 enzymes or cellular transport processes. Research on the metabolism of pipamperone, an antipsychotic of the butyrophenone family, has not yet yielded conclusive results. In the present in vitro study, human cytochrome enzymes were investigated for their possible involvement in the metabolism of pipamperone.</p><p><strong>Methods: </strong>The recombinant human cytochrome enzymes tested, i.e. CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, were commercially available. The U.S. Food and Drug Administration-recommended clinical index substrates were used to establish appropriate incubation conditions for each enzyme. All substrates and their metabolites were analyzed by gas chromatography-mass spectrometry. After incubation, the amount of metabolites formed and the concentration of remaining pipamperone were measured. In addition, the metabolites from these in vitro experiments were compared with the metabolites found in the urine of pipamperone-treated patients and with those produced in a cell culture experiment.</p><p><strong>Results: </strong>Overall, various cytochrome enzymes showed a low turnover of pipamperone. Only CYP2D6 and CYP3A4 caused statistically significant changes in both a decrease in pipamperone concentrations and an increase in metabolites. CYP3A4 proved to be the isoform that metabolized pipamperone most strongly, producing the same metabolite as all other CYP isoenzymes. It is noteworthy that this and other metabolites were also detected in the patients' urine samples.</p><p><strong>Conclusions: </strong>Our results suggest that, alongside the tested cytochrome enzymes, other phase I metabolizing systems likely play a role in pipamperone metabolism.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lithium Prescription in Unipolar Depression: Findings from a Nationwide Greek Cohort Study.","authors":"Vasilios Karageorgiou, Ioannis Michopoulos, Michail Hadjulis, Panagiota Mitrou, Eleftherios Thireos, Konstantinos Mathioudakis, Petros Skapinakis, Rossetos Gournellis","doi":"10.1055/a-2924-4384","DOIUrl":"https://doi.org/10.1055/a-2924-4384","url":null,"abstract":"<p><strong>Abstract: </strong>INTRODUCTION: Lithium is a well-evidenced option for treatment-resistant unipolar depression. However, its use has globally declined over the past two decades and there is little evidence on exactly how unpopular the unipolar augmentation strategy is on the nosological characteristics of patients who still receive it and on primary agents. Real-world epidemiological studies can provide key relevant insights.</p><p><strong>Abstract: </strong>METHODS: We analysed all ICD-10 unipolar depression prescriptions in Greece in the period between 1/2/2019 and 31/1/2020 and identified unipolar depression patients who were prescribed lithium. To benchmark lithium rates against those of other alternatives, we estimated quetiapine and aripiprazole prescription rates in unipolar depression. Logistic regression models were used to locate the diagnostic predictors of lithium prescription. Polypharmacy patterns and co-prescription of potentially interacting drugs were examined.</p><p><strong>Abstract: </strong>RESULTS: Only 1,314 patients (0.174%) with unipolar depression were prescribed lithium, representing a small fraction of the assumed 30% of patients expected to have treatment-resistant depression. This was substantially lower than quetiapine (7.1%) and aripiprazole (1.1%) prescription rates for unipolar depression. Patients who were prescribed lithium were younger, more often men, and mostly managed by psychiatrists. More severe disorder profiles were apparent (24% vs. 6%), with psychotic symptoms and mixed symptomatology more prevalent. The sensitivity analysis showed that, after excluding patients prescribed lithium who received a diagnosis suggestive of bipolarity within the same period, only 785 patients (0.108%) consistently received unipolar diagnoses, with a further drop when other major diagnoses are factored in (0.08%). One in 13 people received a possibly interacting drug, especially thiazide diuretics.</p><p><strong>Abstract: </strong>DISCUSSION: Despite strong evidence for augmentation in treatment-resistant unipolar depression, lithium prescription remains an underappreciated treatment option. In Greece, it is reserved for severe cases, together with selective serotonin reuptake inhibitors/serotonin and norepinephrine reuptake inhibitors and atypical antipsychotics. Possible reasons include a perception of alternatives as safer, further complicated by supply issues.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148685581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Berend Malchow, Paul-Fabian Mühl, Michael Belz, Anke Bramesfeld, Elias Wagner, Jens Wiltfang, Alkomiet Hasan, David Zilles-Wegner
{"title":"Guideline adherence in patients with long-term schizophrenia in Germany: Focus on clozapine and electroconvulsive therapy.","authors":"Berend Malchow, Paul-Fabian Mühl, Michael Belz, Anke Bramesfeld, Elias Wagner, Jens Wiltfang, Alkomiet Hasan, David Zilles-Wegner","doi":"10.1055/a-2899-9948","DOIUrl":"https://doi.org/10.1055/a-2899-9948","url":null,"abstract":"<p><strong>Introduction: </strong>Previous studies suggest a problem in the care of long-term patients in psychiatry, i.e., patients with long hospitalizations and no indication for acute inpatient treatment. Long stays are often associated with treatment resistance, for which evidence-based guideline recommendations exist for patients with schizophrenia. The aim of this study is to assess and characterize long-term patients in German psychiatric clinics and analyze the implementation of guideline recommendations for treatment-resistant schizophrenia.</p><p><strong>Methods: </strong>An anonymous online questionnaire was distributed to the management of 218 acute psychiatric clinics in Germany. The survey covered structural characteristics of the clinic, the number and diagnoses of long-term patients, and the implementation of guideline recommendations for patients with treatment-resistant schizophrenia.</p><p><strong>Results: </strong>At the time of the survey, two-thirds of the responding clinics were treating long-term patients. Over 60% (<i>n</i>=45) of these patients had a diagnosis from the schizophrenia spectrum, with an average length of stay of 267 days. A total of 82.2% of patients with schizophrenia received antipsychotic therapy, 53% received clozapine, and 15.6% received electroconvulsive therapy. The most common reason for not receiving clozapine and electroconvulsive therapy was lack of consent.</p><p><strong>Discussion: </strong>The survey confirms the unresolved problem of long-term patients in acute psychiatric clinics. In addition to demands for improved care structures for people with severe and chronic mental illnesses, the quality of acute psychiatric treatment (guideline adherence) must also be questioned. From an ethical viewpoint, short-term nonvoluntary measures aimed at restoring capacity to consent need to be weighed up against long-term or even permanent detention.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148631226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Di Francesco, Antonio Munafò, Gaetano Catania, Sofia Francesca Aprile, Salvatore Canonico, Carmen Concerto, Alessandro Rodolico, Maria Salvina Signorelli, Stefan Leucht, Filippo Caraci
{"title":"Efficacy and tolerability of nutraceuticals and phytotherapics for antipsychotic-induced weight gain in schizophrenia spectrum disorders: Systematic review and meta-analysis.","authors":"Antonio Di Francesco, Antonio Munafò, Gaetano Catania, Sofia Francesca Aprile, Salvatore Canonico, Carmen Concerto, Alessandro Rodolico, Maria Salvina Signorelli, Stefan Leucht, Filippo Caraci","doi":"10.1055/a-2869-0635","DOIUrl":"https://doi.org/10.1055/a-2869-0635","url":null,"abstract":"<p><strong>Abstract: </strong>Antipsychotic drugs frequently cause metabolic complications in people with schizophrenia spectrum disorders, increasing cardiovascular morbidity and contributing to premature mortality; nutraceutical and phytotherapeutic agents may offer accessible adjunctive strategies, but their efficacy in this setting remains uncertain. We conducted a systematic review and meta-analysis (PROSPERO: CRD42024616494) of randomized controlled trials comparing nutraceuticals/phytotherapics with placebo in adults (18-65 years) with schizophrenia spectrum disorders receiving antipsychotics, including interventions lasting at least 4 weeks. Primary outcomes were body weight change and all-cause treatment discontinuation; secondary outcomes included lipid profile, glucose homeostasis, blood pressure, and anthropometric measures. Two independent reviewers extracted data and assessed study quality using the Cochrane Risk of Bias 2 tool, and meta-analyses primarily used random-effects models. Twenty-one trials (1,426 participants) evaluating 16 interventions were included. Omega-3 fatty acids, probiotics combined with dietary fibers, and Liuyu decoction were each associated with reduced body weight versus placebo, while alpha-lipoic acid showed consistent triglyceride reductions across two independent trials and berberine reduced systolic blood pressure. Discontinuation rates did not differ between groups, but risk of bias was frequently substantial, mainly due to blinding limitations and missing data handling. Overall, alpha-lipoic acid for hypertriglyceridemia and berberine for hypertension have the most consistent multi-trial support, whereas single-trial findings for omega-3s, probiotic combinations, and traditional Chinese medicine preparations require replication; heterogeneity and methodological weaknesses currently preclude broad clinical recommendations, though selected nutraceuticals may be considered for specific metabolic targets.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-07-01Epub Date: 2026-07-02DOI: 10.1055/a-2860-7861
Xenia M Hart, Gerhard Gründer, Christoph Hiemke, Ivana Adamovic, Friederike Amann, Pierre Baumann, Niels Bergemann, Christian Brandt, Hans-Willi Clement, Andreas Conca, Jürgen Deckert, Otto Dietmaier, Gabriel Eckermann, Karin Egberts, Katharina Endres, Nicole Erlacher, Stefanie Fekete, Stefano Ferrea, Vincenzo Florio, Manfred Gerlach, Ekkehard Haen, Martina Hahn, Ursula Havemann-Reinecke, Gudrun Hefner, Wolfgang H Jost, Maxim Kuzin, Gerd Laux, Stefan Leucht, Ignazio Maniscalco, Andreas Menke, Thomas Messer, Rainald Moessner, Daniel J Müller, Thomas Müller, Michael Paulzen, Holger Petri, Philippe Pfeifer, Bruno Pfuhlmann, Peter Riederer, Sibylle C Roll, Maike Scherf-Clavel, Markus Schwarz, Werner Steimer, Julia C Stingl, Sermin Toto, Sven Ulrich, Gerald Zernig, Gabriela Zurek, Stefan Unterecker, Georgios Schoretsanitis
{"title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.","authors":"Xenia M Hart, Gerhard Gründer, Christoph Hiemke, Ivana Adamovic, Friederike Amann, Pierre Baumann, Niels Bergemann, Christian Brandt, Hans-Willi Clement, Andreas Conca, Jürgen Deckert, Otto Dietmaier, Gabriel Eckermann, Karin Egberts, Katharina Endres, Nicole Erlacher, Stefanie Fekete, Stefano Ferrea, Vincenzo Florio, Manfred Gerlach, Ekkehard Haen, Martina Hahn, Ursula Havemann-Reinecke, Gudrun Hefner, Wolfgang H Jost, Maxim Kuzin, Gerd Laux, Stefan Leucht, Ignazio Maniscalco, Andreas Menke, Thomas Messer, Rainald Moessner, Daniel J Müller, Thomas Müller, Michael Paulzen, Holger Petri, Philippe Pfeifer, Bruno Pfuhlmann, Peter Riederer, Sibylle C Roll, Maike Scherf-Clavel, Markus Schwarz, Werner Steimer, Julia C Stingl, Sermin Toto, Sven Ulrich, Gerald Zernig, Gabriela Zurek, Stefan Unterecker, Georgios Schoretsanitis","doi":"10.1055/a-2860-7861","DOIUrl":"10.1055/a-2860-7861","url":null,"abstract":"<p><strong>Abstract: </strong>TDM involves measuring and interpreting drug concentrations in blood plasma or serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a well-established tool for personalized drug treatments. The AGNP-TDM task force initially published guidelines for best practice TDM in 2004, 2011, and 2017. A fundamental methodological revision has now been carried out on how to determine therapeutic reference ranges and dose-related reference ranges transparently and systematically. In the current edition, 50 experts in neuropsychopharmacology offer a complete update of both ranges for each substance following an evidence-based approach. Various types of data were considered for reference range determination, ranging from meta-analyses to drug concentrations expected under recommended doses. Therapeutic reference ranges are now listed for 160 neuropsychiatric drugs, newly included for 30 drugs and revised for 88 drugs. Expected drug concentrations can be calculated based on a revised formula for 162 drugs. Obligatory TDM (i.e. for dose titration) is strongly recommended for 15 neuropsychiatric drugs and recommended for 39 drugs. TDM is classified as useful for 49 drugs and potentially useful for 62 drugs, indicating that it is recommended in specific clinical situations, such as suspected non-adherence, insufficient clinical response despite recommended doses, relapse during maintenance treatment, and many more. The 2026 update includes practical pharmacogenetic recommendations that are directly relevant to TDM. This work integrates a combination of strategies to guide drug treatments in clinical practice using all available tools. A consistent implementation of TDM and pharmacogenetic recommendations will enhance neuropsychopharmacotherapy, improve patient outcomes, and reduce healthcare costs.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"166-295"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PharmacopsychiatryPub Date : 2026-07-01Epub Date: 2026-07-06DOI: 10.1055/a-2897-5020
Georgios Schoretsanitis, Stefan Unterecker, Xenia M Hart
{"title":"Editorial.","authors":"Georgios Schoretsanitis, Stefan Unterecker, Xenia M Hart","doi":"10.1055/a-2897-5020","DOIUrl":"10.1055/a-2897-5020","url":null,"abstract":"","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"164-165"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.","authors":"MariaJose Acuña, Joaquin-Carlos Martin-Muñoz, María-Jesús Muñoz, Francisco-Dionisio Casado, Matilde Blanco-Venzalá, Luisa Rosado-Tejero, Eva Utrera-Caballero, Juan-José Galafate","doi":"10.1055/a-2865-3839","DOIUrl":"https://doi.org/10.1055/a-2865-3839","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the impact of treatment with long-acting injectable antipsychotics on direct healthcare costs in a programme for patients with recent-onset psychosis.</p><p><strong>Methods: </strong>This was an observational, retrospective study. We included all patients admitted to the programme (from July 2015 to April 2020). All costs were recorded and three groups were compared: those receiving oral antipsychotics; those receiving oral treatment initially but subsequently switching before long-acting injectable antipsychotics; and those receiving after long-acting injectable antipsychotics.</p><p><strong>Results: </strong>A total of 136 patients were included: 68 patients in the oral antipsychotics group and 34 patients in each of the other two groups. The average total healthcare cost per person/y was €11,347 in the oral antipsychotics group, €49,001 in the before long-acting injectable antipsychotics group, and €27,170 in the after long-acting injectable antipsychotics group. The comparisons between the first group and the other two were significant and between the after long-acting injectable antipsychotics vs before long-acting injectable antipsychotics groups (<i>p</i><0.01, Mann-Whitney <i>U</i> test). These differences were related to the costs of psychiatric admissions, with an average per person/y of €2,252 (oral antipsychotics group), €22,947 (before long-acting injectable antipsychotics group) and only €777 in the after long-acting injectable antipsychotics group. The only prior clinical or demographic distinction between the three groups was the presence of substance abuse disorder, 41.2% in the oral treatment group vs. 70.6% in the long-acting injectable antipsychotics group (<i>p</i>=0.003 <i>X</i> <sup>2</sup> Pearson 99%; confidence interval: 0.002-0.005). In patients with recent-onset psychosis and comorbid substance abuse disorder, treatment with long-acting injectable antipsychotics, despite the higher cost of this medication, may be associated with a reduction in total direct healthcare costs. In our study, it saves €21,831 per patient/y.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xenia M Hart, Dusan Hirjak, Chin B Eap, Luzie Eichentopf, Stefan Fritze, Xenija Marie Lense, Dennis Scharf, Claudia Schilling, Nina Schwind, Philip Post, Katja Wesner, Gerhard Gründer
{"title":"High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.","authors":"Xenia M Hart, Dusan Hirjak, Chin B Eap, Luzie Eichentopf, Stefan Fritze, Xenija Marie Lense, Dennis Scharf, Claudia Schilling, Nina Schwind, Philip Post, Katja Wesner, Gerhard Gründer","doi":"10.1055/a-2868-3000","DOIUrl":"https://doi.org/10.1055/a-2868-3000","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Clozapine is an effective antipsychotic used in treatment-resistant schizophrenia, but high serum levels may increase side effects. This study aimed to examine the efficacy and tolerability profile of clozapine in a naturalistic setting. The impact of multiple factors, specifically CYP1A2 genotypes, smoking, and fluvoxamine coadministration, on CYP1A2 enzyme activity was assessed as a secondary exploratory end point.</p><p><strong>Study design: </strong>In this prospective, observational study, 32 patients receiving stable clozapine therapy were observed over a 24-hour period at the Central Institute for Mental Health, Mannheim. Clozapine blood levels were measured via liquid chromatography-mass spectrometry and the MyCare Clozapine Assay.</p><p><strong>Results: </strong>Clozapine levels above 600 ng/mL were not associated with increased clinical efficacy but were linked to more side effects. Sleep quality was generally poor, and daytime sedation was frequent. While coadministration with the CYP1A2 inhibitor fluvoxamine led to a dose-corrected increase in clozapine levels of approximately 50%; smoking reduced clozapine (-36%) and norclozapine (-32%) levels.</p><p><strong>Conclusions: </strong>Clozapine levels above the therapeutic reference range may not provide additional benefits and could increase side effects. Therapeutic drug monitoring is an essential clinical practice tool, especially when using comedication or in smokers. Overall, these findings should be interpreted as exploratory and supportive of existing therapeutic guidance because of the small sample size and naturalistic study design.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147983096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rates of Hypoprolactinemia in Bipolar Patients Receiving Once-monthly Long-acting Injectable Aripiprazole.","authors":"Fatma Simsek","doi":"10.1055/a-2861-6690","DOIUrl":"https://doi.org/10.1055/a-2861-6690","url":null,"abstract":"<p><strong>Introduction: </strong>Hypoprolactinemia, an often overlooked condition in psychiatric practice, has been suggested to be associated with potential adverse effects on sexual and metabolic functions, similar to those reported in hyperprolactinemia. Recently, numerous studies have indicated that oral aripiprazole can lead to hypoprolactinemia in patients with various psychiatric disorders. However, the frequency and severity of hypoprolactinemia in bipolar patients receiving a 400-mg dose of once-monthly long-acting injectable aripiprazole remain unknown. This study aimed to assess the effects of once-monthly long-acting (400 mg) injectable aripiprazole on prolactin levels in patients with bipolar disorder.</p><p><strong>Methods: </strong>Fifty patients with bipolar disorder (25 women and 25 men) receiving the 400-mg dose of once-monthly long-acting injectable aripiprazole, either as monotherapy or in combination with other psychiatric medications, were recruited for this study.</p><p><strong>Results: </strong>Overall, the rate of hypoprolactinemia was 52% among the study participants. When stratified by sex, the prevalence was 68% in men and 36% in women. In addition, 28% of male patients and 4% of female patients had serum prolactin levels below 1 ng/mL. Mean serum prolactin levels were significantly higher in women than in men (<i>z</i>=- 3.435, <i>p</i>=0.001). No significant correlation was observed between serum prolactin concentrations and age or treatment duration in either sex.</p><p><strong>Discussion: </strong>Once-monthly injectable aripiprazole treatment in bipolar disorder was associated with a relatively high prevalence of hypoprolactinemia in both female and male patients. Given emerging evidence of potential metabolic and sexual effects of hypoprolactinemia, monitoring prolactin levels may be clinically relevant in patients receiving injectable aripiprazole.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}